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Abstract: The molecular study of fat cell development in the human body is essential for our
understanding of obesity and related diseases. Mesenchymal stem/stromal cells (MSC) are the ideal
source to study fat formation as they are the progenitors of adipocytes. In this work, we used human
MSCs, received from surgery waste, and differentiated them into fat adipocytes. The combination of
several layers of information coming from lipidomics, metabolomics and proteomics enabled network
analysis of the biochemical pathways in adipogenesis. Simultaneous analysis of metabolites, lipids,
and proteins in cell culture is challenging due to the compound’s chemical difference, so most studies
involve separate analysis with unimolecular strategies. In this study, we employed a multimolecular
approach using a two–phase extraction to monitor the crosstalk between lipid metabolism and
protein-based signaling in a single sample (~105 cells). We developed an innovative analytical
workflow including standardization with in-house produced 13C isotopically labeled compounds,
hyphenated high-end mass spectrometry (high-resolution Orbitrap MS), and chromatography (HILIC,
RP) for simultaneous untargeted screening and targeted quantification. Metabolite and lipid
concentrations ranged over three to four orders of magnitude and were detected down to the low fmol
(absolute on column) level. Biological validation and data interpretation of the multiomics workflow
was performed based on proteomics network reconstruction, metabolic modelling (MetaboAnalyst
4.0), and pathway analysis (OmicsNet). Comparing MSCs and adipocytes, we observed significant
regulation of different metabolites and lipids such as triglycerides, gangliosides, and carnitine with
113 fully reprogrammed pathways. The observed changes are in accordance with literature findings
dealing with adipogenic differentiation of MSC. These results are a proof of principle for the power
of multimolecular extraction combined with orthogonal LC-MS assays and network construction.
Considering the analytical and biological validation performed in this study, we conclude that the
proposed multiomics workflow is ideally suited for comprehensive follow-up studies on adipogenesis
and is fit for purpose for different applications with a high potential to understand the complex
pathophysiology of diseases.
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1. Introduction
In the context of obesity-related diseases it is essential to understand the molecular mechanisms
that govern the formation of fat cells from stem cells. Mesenchymal stem/stromal cells (MSCs)
are multipotent stem cells and the actual progenitors of fat cells/adipocytes [1]. MSCs are easily
accessible as they can be derived from surgical waste or biopsies, i.e., bone marrow, birth-associated
tissue, and adipose tissue. Due to their high proliferation capacity, immune-modulatory functions,
and potential to differentiate into multiple lineages, MSCs carry a huge clinical promise in cell-based
therapies, immunomodulation, and tissue engineering [2–5]. In contrast, induced pluripotent stem cells
(iPSCs) are still not considered as safe since they are genetically not stable [6]. Furthermore, MSCs are
ethically not questionable like embryonic stem cells. Today, adipose tissue is the predominant cell
source for MSCs [2,7] as they can be obtained more easily and efficiently than from bone marrow [4].
The process of adipocyte formation, also known as adipogenesis, is regulated by a network of complex
molecular processes. Adipocyte differentiation acts via signal transduction of hormones, growth factors,
metabolites, lipids, and specific protein receptors mediating external growth and differentiation signals
through a cascade of intracellular events. In general, fat cell differentiation is triggered by the ceramide
and peroxisomal proliferator-activated receptor gamma (PPARγ) [8–10]. Insulin and insulin-like
growth factor 1 (IGF-1) are required for fat cell formation and activate distinct downstream signal
transduction pathways such as (1) a phosphorylation-dephosphorylation mechanism subsequent
to IGF-1 tyrosine phosphorylation or (2) insulin activation of the phosphatidylinositol 3-kinase
pathway [11]. During the terminal differentiation phase, adipocytes’ de novo lipogenesis and insulin
sensitivity is highly increased. Protein and mRNA levels for enzymes (e.g., stearoyl-CoA desaturase,
glycerol-3-phosphate dehydrogenase, and fatty acid synthase) involved in triacylglycerol metabolism
are increased 10–100-fold upon fat cell formation [11].
In order to follow MSC differentiation into fat cells, suitable analytical workflows are necessary.
Omics-based strategies are ideal for adipocyte differentiation analysis as they are based on the
observation of a subset of molecules in one organism. In this work, we apply a multiomics
workflow combining metabolomics, lipidomics, and proteomics. Mass spectrometry (MS) based
multiomics strategies are extremely powerful due to their unrivaled potential to monitor an entire set
of molecules in order to follow cellular metabolism and perturbations [12–14]. The combination of
liquid chromatography (LC) with high-resolution MS is ideally suited for multimolecular chemical
analysis, as LC-MS enables identification and quantification by (1) retention time, (2) accurate mass,
and (3) fragmentation pattern of hundreds to thousands of compounds in parallel. Metabolomics of
stem and fat cells provides information on the phenotypic change of small metabolites involved in the
differentiation process. With lipid droplet formation as a hallmark of adipogenic differentiation [11],
lipidomics is able to reflect elevated lipid content at the same time providing information on MSCs
and adipose tissue lipid patterns. Proteomics on the other hand, enables to monitor important
protein key players involved in fat cell formation. In our workflow, we aim to merge targeted
quantification and non-targeted screening of metabolites and lipids to follow MSC differentiation
in adipocytes. The absolutely accurate quantification of several hundred lipids remains a field of
analytical development, as desirable lipid compound-specific standardization is a challenge due to the
complexity of the lipidome. Recently, we developed the novel Lipidome Isotope Labeling of Yeast (LILY)
technology for in vivo labeling of yeast to produce eukaryotic lipid standards [15,16]. With our in vivo
labeling approach, several hundred stable-isotope-labeled lipids can be simultaneously produced,
enabling us to follow lipids as key players in fat cell differentiation. Isotope dilution approaches
involving stable-isotope-labeled lipid and metabolite standards can account for any error accumulated
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in the analytical chain of sample preparation, storage, and measurement. Using isotope dilution
in combination with high-end chromatography and MS instrumentation for the analysis of MSCs
and adipocyte differentiation will provide us with enhanced data matrices as an ideal starting point
to build metabolic models. MSC differentiation affects numerous cellular metabolic pathways and
signaling cascades. Mathematical metabolic models can reveal metabolic characteristics in these
complex regulatory networks [17]. Based on such genome-scale models, essential metabolites, lipids,
and proteins which are key to cell differentiation can be identified. For example, a genome-scale
study on metabolic network model of bone marrow-derived MSCs has previously been presented [18].
A successful model was developed to identify ways to increase stem cell proliferation and differentiation,
providing evidence for the key role of mathematical modelling in biomedical research. Thus, applying
a combination of genome-scale modelling and experimental large-scale omics-analysis together with
multivariate statistics or pattern recognition [19] promises to yield significant advances in the complex
field of adipogenic differentiation.
The mechanistic understanding of fat cell development in the human body is essential for the
treatment of obesity-related diseases. However, a high fraction of studies on the mechanisms that
direct adipogenic differentiation rely on mouse models or murine cell lines [3,20–23]. In the context
of cell-based therapies, translational aspects are of utmost importance as cells from different species
might act differently. For example, the in vitro proliferation of human MSCs exhibits a relatively
low frequency of oncogenic transformation in stark contrast to murine MSCs which frequently gain
chromosomal defects in vitro and often produce fibrosarcomas when injected back into mice [5,24,25].
To enable potential translation of our results, we decided to use human primary MSCs in early passages
for this study. In this work, we present a novel MS-based multiomics strategy to analyze adipogenesis
in human MSCs relying on the combination of high-end MS and chromatography, isotopic dilution
and network analysis.
2. Results
2.1. Development of a Multiomics Workflow for the Analysis of Adipogenic Differentiation from MSCs
Primary adipose tissue-derived MSCs (MSC0) were cultivated in adipogenic differentiation
medium for 21 days (MSC21). Successful adipogenic differentiation was observed by morphological
changes of the cells and lipid vacuole formation (Figure 1). In order to perform a representative systems
biology experiment, the multiomics data should ideally be generated from the same set of samples to
allow for direct comparison under the same conditions [26]. To meet these requirements, we applied
an adapted two-phase extraction procedure for MSC and fat cells (n = 5) to sequentially extract
lipids, metabolites, and proteins [10]. Sequential lipid, metabolite, and protein extraction by MTBE
provided the advantage of multimolecular information from one sample without the drawback in
sample handling by protein precipitation in the interphase, then chloroform/methanol/water extraction
systems were used [27]. We modified the original SIMPLEX protocol [10] by using nitrogen quenching
so that trypsin was avoided and less amounts of human MSCs and adipocytes (~105 cells) were
needed. We developed a multiomics strategy based on hyphenated high-end mass spectrometry and
chromatography for non-targeted screening and targeted quantification.
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Figure 1. Oil Red O staining of adipose tissue-derived mesenchymal stem/stromal cells (MSCs) after 0
and 21 days cultivation in the adipogenic differentiation medium (ADM) or control medium (CM).
The scale bar indicates 100 µm.
Protein information was generated by state of the art LC-MS/MS shotgun proteomics and was
used to build metabolic networks linked to human genomic sequences. Metabolite and lipid profiling
in MSCs and adipocytes was performed using a novel HILIC-RP dual injection strategy combined
with high-resolution Orbitrap-MS [28]. Merging metabolomics and lipidomics assays is usually
compromised by different extraction procedures needed (high polarity ranges from very polar small
metabolites to medium-mass nonpolar lipids), and typically the two approaches deliver separate data
sets. Using the parallel HILIC-RP method, two extracts can be measured on two columns in one
analytical run so that metabolite and lipid information is generated in 32 min. Concentrations ranging
over three to four orders of magnitude can be assessed by the HILIC-RP-MS assay [28]. The addition
of 13C-labeled metabolite/lipid standards enabled us to merge targeted quantification with untargeted
compound screening in MSCs and adipocytes. Low sample amounts of MSCs and adipocytes (~105
cells) were needed for detecting fmol absolute on the column in the parallel HILIC-RP method. This is
significantly lower than a recent shotgun lipidomics approach used for the quantitative analysis of
white and brown adipose tissue, where pmol of lipids were theoretically detectable [29] highlighting
the sensitivity advantage when LC-MS based workflows are applied.
2.2. Targeted Lipidomics and Metabolomics Comparing MSCs and Adipocytes
For targeted analysis, we employed isotopically 13C-labeled metabolite and lipid standards
produced in our laboratory for standardization [15,30,31] to follow fat cell differentiation of MSCs.
Absolute compound-specific quantification (n = 3) of 12 lipids and 54 metabolites (compound- specific
quantification using endogenous/13C-labeled pairs) was performed using external calibration (8
standards within the calibration range of 0.1–25 µM), with internal standardization by in-house
produced 13C-labeled standards and protein normalization. The selection of the targeted analytes
was performed on the available standards mixes and corresponding 13C-labeled lipids/metabolites
(Table S1). All lipids and metabolites quantified in MSCs/adipocytes were in the range of nmol to fmol
range per mg protein with limits of detection of fmol absolute on column. Isotope dilution and the
use of the LILY lipids enhanced the quantification significantly (Figures A1 and A2), i.e., triglycerides
(TG) 54:6 (R2 of 0.9812 vs. 0.7146 for label-free quantification). Once more showing the advantage
of using our in-house produced standards for quantitation [15,16]. The comparison of the targeted
metabolite and lipid quantification in MSCs and adipocytes revealed significant downregulation (fold
change > 2, p-value < 0.05) of GMP, S-adensoyl-methionine, asparagine, L-cystathionine, adenosine,
5’-deoxy-5’-methylthioadenosine, and adenine in adipocytes. The amino acids showed a general trend
to be less abundant in adipocytes (Figure A3A), whereas triglycerides and lipid precursors such as
carnitine and propionyl-L-carnitine were increased upon differentiation (Figure A3B,C), which can be
explained by the formation of lipid droplets upon differentiation of the MSCs. Separation of MSC and
adipocytes was observed by principal component analysis using the targeted metabolite and lipid
data set (Figure 2A,B). Due to the low number of replicates (n = 3) a profound statistical evaluation
of significance is not possible here. However, adipocyte (MSC21) metabolite and lipid data showed
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a much higher variance than before differentiation (MSC0). This indicates a diversification of the
metabolome and lipidome due to differentiation which remains to be tested for its significance in
future studies.Molecules 2019, 24, x 5 of 18 
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2.3. Non-targeted Lipidomics and Metabolomics Comparing MSCs and Adipocytes
Non-targeted lipid and metabolite analysis revealed significant changes (fold change > 2, p-value
< 0.05,) comparing undifferentiated MSCs (MSC0, cells before differentiation initiation, n = 5) with
MSCs differentiated into the adipogenic lineage (MSC21, cells after 21 days of adipogenic incubation,
n = 5). A general increase in molecular complexity in differentiated adipocytes was observed indicated
by the higher number of identified metabolites and lipids (Figure 3). After filtering (Compound
Discoverer 3.0: background removal using extraction and eluent blanks, area > 50,000, MetaboAnalyst:
Interquartile range) and normalization (mean-centered and divided by the standard deviation of
each variable in MetaboAnalyst), 171 compounds were significantly upregulated and 24 compounds
were downregulated in adipocytes. Overall, 2650 compounds were identified in the lipid fraction
of both sample groups which is three times higher compared to the metabolite fraction with 839
compounds (Figure 3). This observation reflects the formation of lipid droplets as a hallmark for
adipogenic differentiation, and is consistent with a general trend of summed area increase in adipocytes
detected for most of the abundant lipid classes, namely triglycerides (TG), phosphatidylcholine
(PC), lysophosphatidylcholine (LPC), sphingomyelin (SM), ceramides (Cer), and diglycerides (DG)
(Figure A4, Table S1). The upregulation was significant in TGs (Figure A4), which are the main
constituents of lipid droplets [3]. For the other lipid classes detected belonging to the category of
phospholipids, no significant changes (phosphatidylethanolamines (PE), phosphatidylinositols (PI),
phosphatidylserines (PS), lysophosphatidyl-ethanolamines (LPE)) were detected. Overall, an indication
towards phospholipid remodeling (Figure A4, Table S1) upon adipogenic differentiation/lipid droplet
formation was observed [33].
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Figure 3. Differential analysis of lipids and metabolites. Volcano plot (derived from untargeted LC-MS)
of compounds from primary MSCs and adipocytes using MetaboAnalyst 4.0 (with p-value settings 0.05,
interquartile filter) [32]. HILIC-RP-HRMS (positive mode) revealed that 195 out of 3498 compounds
were significantly regulated (p-value < 0.05, fold change (FC) > 2). Both lipids and metabolites were
significantly upregulated in adipocytes compared to MSCs.
2.4. Biological Validation and Data Interpretation of the Multiomics Workflow
2.4.1. Proteomics Network Reconstruction, Metabolic Modelling and Pathway Analysis
The shotgun proteomic analysis of non-differentiated and differentiated MSCs identified 1869
proteins (Table S1, protein IDs, n = 2) and revealed significant dynamics of the cellular proteome
during the differentiation process. The observed protein changes are in accordance with previously
published proteomics data on human adult stem cell adipogenesis, e.g. matching upregulation of
apolipoprotein, fatty acid binding protein, glycerol-3-phosphate dehydrogenase, fatty acid synthase,
phosphoglycerate synthase, and downregulation of platelet activating factor, acetylhydrolase 1B,
and annexin was observed [34]. The upregulation of glycerol-3-phosphate dehydrogenase and fatty
acid synthase was also reported as a consequence of increased triacylglycerol metabolism upon lipid
droplet formation in adipocytes [11].
Based on the human genome-scale consensus model Recon 2.4, proteomic data were applied to
reconstruct context-specific networks which reflect the specific proteomic constitution of MSCs before
and after differentiation. In total, 165 metabolic reactions and processes were fully reprogrammed
on the proteome level during differentiation (Figure A5). The strongest effects were observed for
reprogramming of reactions in fatty acid metabolism (oxidation, synthesis, eicosanoid, inositol
phosphate, and bile acid metabolism) and transport processes (peroxisomal and extracellular, as well
as endoplasmatic reticular transport) (Table S1, Figure A5).
Using the protein information together with the generated metabolite and lipid (combining
targeted and non-targeted lists with median areas/concentrations for comparison of MSCS and
adipocytes) data (Table S1), multiomics pathway analysis was performed (OmicsNet [35]). Comparing
MSCs and adipocytes, 113 significantly regulated pathways (p-value > 0.05) (Table S2) were identified
in four different correlation networks including one major network (continent network-101 regulated
pathways) and three subnetworks (island networks for glycerolipids-7 pathways; glutathione
disulfide-2 pathways, carnitine- 3 pathways). Adenosine triphosphate (ATP) and adenosine
monophosphate (AMP) showed the highest correlation degree (922, 141 respectively) within the
protein-metabolite network (Figure 4A,C) due to the expected change in energy metabolism and
phosphorylation-dephosphorylation upon fat differentiation [11]. Several biological relevant and
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expected active pathways were identified (Figure 4A–C) including (1) glycerophospholipid signaling
(Figure 4A,B, Table S2, network 1) [10,36], (2) the insulin pathway (Figure 4C, Table S2, network
1) [8–10], (3) glycerolipid (triglycerides regulating) pathway with corresponding fat digestion and
absorption (Figure A6A, Table S2, subnetwork 2) [11,37,38], (4) carnitine regulation within the fatty acid
metabolism, PPAR signaling, and adipocytokine signaling pathways (Figure A6B, Table S2, subnetwork
4) [39–41], and (5) glutathione disulfide within arachidonic acid metabolism and oxidation related
pathways (Table S2, subnetwork 3) [42–44]. Interestingly, triglycerides- and carnitine-related pathways
were separated as individual subnetworks (Figure A6A,B, Table S2). Both compound classes are known
to be highly regulated [11,39] in adipogenesis and will be discussed in more detail below.
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2.4.2. Carnitine Regulation
Increased concentrations of carnitine and propionyl-L-carnitine ere observed in adipocytes by
targeted analysis (Figure A3C) with a significant regulation of carnitine related pathways (Figure A6B,
Table S2, subnetwork 4). Carnitine synthesis is necessary for fatty acid oxidation and fatty acid
transport fro the cytosol to the itochondria [45] and is kno n to i prove insulin sensitivity of
adipocytes [46], an inherent characteristic of adipose tissue. Interestingly, upregulated acyl-carnitine
levels are associated ith the pro otion of the differentiation process of e bryonic ste cells in
different cell types [42]. Additionally, carnitine and acetyl-carnitine were found to reduce adipogenesis
but stimulate osteogenesis and chondrogenesis in human MSCs by regulating the mitochondrial
etabolisms [39]. It is also known to attenuate lipid accumulation in adipocytes via downregulation
of PPARγ, a major adipocyte-specific transcription factor [47].
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2.4.3. Trigylcerides Upregulation in Lipid Droplets of Adipocytes
A major increase of TGs in adipocytes was observed in the targeted lipid analysis (Figure A3B) and
the number of identifications received by non-targeted lipidomics (Figure 3). Additionally, triglycerides
were involved in several significantly regulated pathways of the multiomics data (Figure A6A, Table S2,
subnetwork 2). Comparing the 10 most regulated compounds in the classes of MSCs and adipocytes
(from the combined untargeted metabolite and lipid data set), several interesting m/z variables were
found by partial least square and heat map analysis (MetaboAnalyst 4.0 [32]). Some of them could
be further identified by a database search (Lipid Search) and manual curation. Four upregulated
triglycerides in adipocytes were annotated based on accurate mass, fragmentation and retention time,
namely TG (16:0_16_1_18:0), TG (16:0_16:1_18:1), TG (16:1_18_0_18_0), and TG (16:0_18:1_18:1). TGs are
the major constituents of lipid droplets representative of successful adipogenic differentiation. Expected
lipid droplet formation was induced in the adipocytes (Figure 1) upon medium change and reflected in
the list of regulated proteins by the increase of, for example, fatty acid synthase, glycerol-3-phosphate
dehydrogenase, and malic enzyme, which are all known to increase the triglyceride metabolism [11].
2.4.4. Gangliosides are Involved in Adipocyte Differentiation and Insulin Sensitivity
The m/z for the gangliosides GM3(d18:1/16:0) and GM3(d18:1/22:1) were listed within the 10
most regulated compounds identified (partial least square, heat map, MetaboAnalyst [32]) when
comparing MSCs and adipocytes. We annotated them manually by m/z, fragmentation, and matching
retention times (in positive and negative MS mode), and observed an upregulation in adipocytes
by a factor of 20 and 30 respectively. Comparing the ganglioside glycosphingolipid fragmentation
pattern (Figure A7), the ceramide moiety was determined in the positive ion mode (characteristic
sphingosine fragments at m/z 264 and 282) and the glycan residue was annotated in the negative
ion mode (characteristic N-acetylneuraminic acid fragment ion at m/z 290). Additionally, a series
of gangliosides (GM3(32:1;2) GM3(32:0;2), GM3(33:1;2), GM3(34:0;2), GM3(34:2;2), GM3(35:1;2),
GM3(36:0;2), GM3(36:1;2), GM3(36:2;2), GM3(38:1;2), GM3(40:0;2), GM3(40:1;2), GM3(40:2;2),
GM3(41:0;2), GM3(41:1;2), GM3(41:2;2), GM3(42:0;2), GM3(42:1;2), GM3(43:1;2), and GM3(43:2;2))
was identified by m/z, elution order depending on the number of double bonds and fatty acid
chain length, as well as matching retention time (elution: 22.3–28.3 min) between the different MS
modes (+/−). Ten (GM3(33:1;2), GM3(35:1;2), GM3(36:0;2), GM3(41:0;2), GM3(41:1;2), GM3(41:2;2),
GM3(42:0;2), GM3(42:1;2), GM3(43:1;2), and GM3(43:2;2)) of the 22 identified gangliosides were
only found in adipocytes and all other gangliosides were found in lower abundances in MSCs.
This is of special interest, as GM3 gangliosides are part of the sphingolipid metabolism identified
by protein-metabolite network data (Table S2(4)). The connection of ganglioside increase upon
adipogenesis was further supported by the upregulation of the ganglioside GM2 activator protein
in adipocytes, which is able to extract GM2 molecules from membranes to hydrolyze them to GM3.
The enzymatic activity of ganglioside GM2 activator protein strongly depends on the sphingolipid and
membrane lipid composition [48]. Gangliosides were proposed as a new class of stem cell markers,
e.g. GD1a increase for favored osteogenesis in MSCs [49]. They were further found to be involved
in the differentiation of MSCs into osteoblasts and neural cells [50] and are generally associated
with the insulin metabolic signaling in adipocytes [51]. Insulin is required for fat cell formation
activating distinct signal transduction pathways, such as phosphorylation-dephosphorylation or the
phosphatidylinositol-3-kinase pathway [10]. Major reprogramming of related pathways (insulin,
glycerolipid, sphingolipid, phosphatidylinositol pathway) was also confirmed by the multiomics
data (Figure 4, Table S2, subnetwork 1). Additionally, we observed upregulation of perilipin-4 upon
adipocyte differentiation of MSCs (Table S1) which is an adipocyte phosphoprotein present in the
periphery of lipid storage droplets [3,11].
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3. Discussion
The presented multiomics study on the adipogenic differentiation of MSCs is a proof of principle
for the power of multimolecular extraction procedures combined with orthogonal LC-MS assays and
network construction. Merging metabolomics and lipidomics assays was possible by adapting (no
trypsin, less starting cell number) the original SIMPLEX protocol [10] for sequential lipid, metabolite,
and protein extraction. Followed by the HILIC-RP dual injection setup, metabolite and lipid information
was generated from the same sample in one analytical run. Additionally, targeted quantification
by 13C-labeled metabolite/lipid standards could be performed with untargeted compound screening
in the same assay, so that sample amounts needed were significantly reduced. The 13C-labeled
metabolites/lipids can be potentially used for normalization of non-targeted LC-MS based multiomics
data, which was recently shown to be possible for lipidomics data [52] and represents an important
future goal. LC-MS assays are especially useful when low abundant metabolites and lipids are of
interest as the chromatographic separation offers cleanup of the sample matrix, higher linear dynamic
range, and additional compound identification by retention time information. The power for the
detection of unknown low abundant compounds was impressively shown by the example of GM3
gangliosides in MSCs and adipocytes. None of the gangliosides could be annotated by a database
search, although the used in silico database included all types of gangliosides (GM1, GM2, GM3).
Only when comparing the non-targeted datasets of MSCs and adipocytes, two of these high mass (>1000
m/z) glycosphingolipids showed up as interesting differentiating unknown compound. Using manual
curation of the fragmentation pattern, matching retention times in the positive and negative ion mode,
and retention time order, 22 different gangliosides could be successfully annotated and were further
confirmed by the upregulation of the ganglioside GM2 activator protein. Despite the limited sample
number of the assay, all biological observations for the regulation of triglycerides [3,8], gangliosides [51],
and reprogrammed pathways [23] in adipocytes are in accordance with the literature. Further biological
interpretation of the data is beyond the scope of this work. Future studies will focus on in-depth analysis
of fat differentiation involving time-series experiments, tracer studies, and the comparison of different
fat cell tissue types. Additionally, targeted LC-MS based assays will be developed for metabolite and
lipid classes relevant in adipogenesis such as triglycerides, acyl-carnitines, or gangliosides.
The presented biotechnology workflow based on adult human MSCs from surgical waste represents
a general strategy to avoid animal experiments and induced pluripotent stem cells [6,53] for certain
clinical studies and drug testing. The performed biological validation (literature search, identification
of relevant regulated compounds and pathways) combined with the analytical method validation
(analytical figures of merit; use of commercially available standards as well as in-house produced
labeled metabolites and lipids; database annotation based on RT, accurate mass and fragmentation
pattern; additional manual curation), lets us conclude that the presented workflow is fit for purpose
for other cell culture or tissue-based multiomics studies. LC-MS based multiomics workflows enable
to follow the complex pathophysiology of diseases among various other applications. Our multiomics
workflow offers comprehensive multimolecular information based on a single sample (using the
sequential extraction approach) and low analysis time. We hypothesize that reproducible diagnostic
high-throughput LC-MS based assays can be implemented by automatic sample extraction and
data evaluation.
4. Materials and Methods
4.1. Cell Culture
The use of human tissue was approved by the ethics committee of the Medical University Vienna,
Austria (EK Nr. 957/2011, 30 January 2013) and the donor gave written consent. Human adipose
tissue-derived MSCs were isolated from a female donor (age 29) within 3–6 h after surgery as
described before [54]. Briefly, adipose tissue was obtained from abdominoplasty, minced with scissors,
and digested with collagenase type I (Sigma Aldrich, St. Louis, MO, USA). After several centrifugation
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and washing steps, the stromal vascular fracture was released in a cell culture flask (Sarstedt, Nümbrecht,
Germany) with standard cell culture medium composed of MEM alpha (Thermo Fisher Scientific,
Waltham, MA, USA), 0.5% gentamycin (Lonza, Basel, Switzerland), 2.5% human platelet lysate (hPL;
PL BioScience, Aachen, Germany), and 1 U/mL heparin (Ratiopharm, Ulm, Germany), and incubated
in a humidified incubator at 37 ◦C and 5% CO2. Subsequently, MSCs were selected by plastic adherence
and cryo-preserved in 77.5% MEM alpha, 12.5% hPL, 10% DMSO (Sigma Aldrich), and 1 U/mL
heparin (defined as passage 0, P0). For the adipogenic differentiation, cells were thawed at passage 0
and further expanded for two passages in T-flasks. After harvest via accutase (GE healthcare, Little
Chalfont, UK) treatment, MSCs were seeded at 4.000 cells/cm2 in a 6-well plate (Sarstedt, Nümbrecht,
Germany), coated with 2 µg/cm2 fibronectin (Sigma, St. Louis, MO, USA), and 2 mL of CM was added.
Upon confluency, the medium was changed to adipogenic differentiation medium (ADM; Miltenyi,
Bergisch-Gladbach, Germany), supplemented with 0.5% gentamycin, and the cells were cultured for
21 days, while the medium was changed every 2–3 days. Undifferentiated MSCs at day 0 served as
a control. Subsequently, the cells were fixed with 4% paraformaldehyde (Sigma, St. Louis, MO, USA),
washed with ddH2O and stained with Oil Red O solution (Sigma, St. Louis, MO, USA). The staining of
lipid vacuoles was observed by bright-field microscopy (DMIL LED with camera ICC50HD; both Leica,
Wetzlar, Germany).
4.2. Multiomics
All solvents were LC-MS grade. Metabolite and lipid standards were from Sigma, Carbosynth
(Compton Berkshire, England) or Avanti Polar Lipids, Inc. (Alabaster, Alabama, USA) and were
weighed and dissolved in an appropriate solvent. A multi-metabolite mix (148 metabolites) and
multi-lipid mix (76 lipids) were prepared (a comprehensive list of the standards can be found in
Table S1). A metabolite and lipid 13C-labeled standard mix was prepared using the fully 13C-labeled
internal standard from ISOtopic solutions e.U. (Vienna, Austria), combined with an in-house produced
13C-labeled lipid LILY triglyceride fraction and reconstituted in 50% MeOH. The MSC and adipocytes
cells were quenched directly on the 6-well plate using liquid nitrogen prior to storage at −80 ◦C
until sample preparation. The adherent cells (~105 per sample) were harvested (5 samples per
MSC0/MSC21 condition, 2 medium blanks) using a cell scraper and extracted with a mixture of
methanol, methyl-tert-butylether, and 10 mM ammonium formate. The adapted SIMPLEX two-phase
extraction preparation [10] enabled the collection of the lipid fraction (upper phase), the metabolite
fraction (lower phase), and the protein pellet. All samples (n = 5 per condition) were used for
non-targeted analysis. Part of the samples were spiked (n = 3 per condition) with 13C isotopically
labeled metabolites and LILY lipids for targeted quantification. This fraction was used for absolute
compound-specific quantification by external calibration (0.1, 0.25, 0.5, 0.75, 1, 5, 10, 25 µM) with the
commercially available standards (multi-metabolite, multi-lipid mix) and internal standardization by
13C-labeled metabolites and lipids.
A novel HILIC-RP DUAL injection strategy combined with high-resolution Orbitrap-MS was
applied for the simultaneous analysis of small polar metabolites and lipids [28] of the MSC samples.
Briefly, a Vanquish Duo UHPLC system (Thermo Fisher Scientific) equipped with an autosampler with
two injection units, two binary pumps and a column compartment was used to enable parallel HILIC
and RP analyses. A SeQuant® ZIC®-pHILIC column (150 × 2.1 mm, 5 µm, polymer, Merck-Millipore)
was used with gradient elution under alkaline conditions (mobile phase A: 90% 10 mM ammonium
bicarbonate, pH 9.2/10% ACN; mobile phase B 100% ACN) combined with an Acquity HSS T3 (2.1
mm × 150 mm, 1.8 µm, Waters) RP column (mobile phase A: ACN/H2O 3:2, v/v, solvent B: IPA/ACN
9:1, v/v) using a VanGuard precolumn (2.1 mm × 5 mm, 100 Å, 1.8 µm). Two different gradients were
applied for HILIC and RP with a total run time of 32 min as described before [28] using a flow rate
of 300/250 µL min−1 and an injection volume of 5 µL. An additional 2-positional 6-port valve and
the use of a T-piece in front of the mass spectrometer enabled to deliver the HILIC (0–11 min) or RP
(11–32 min) eluent to the MS, while the other separation eluent was directed to waste. High-resolution
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mass spectrometry in positive and negative mode was conducted on a high field Thermo Scientific™ Q
Exactive HF™ quadrupole-Orbitrap mass spectrometer equipped with an electrospray source using
Full-MS (resolution 120,000 for quantification, positive mode only) and ddMS (resolution 30,000,
positive and negative mode, Top-15) for identification. Detailed information on the dual injection
HILIC-RP-MS workflow can be found in the supplementary information of Appendix B.
The protein fractions containing the isotopically spiked samples (n = 3) were determined
by Bradford assay (Pierce™ Coomassie Plus Assay Kit) and used for normalization. The other
protein pellets (n = 2) were used for shotgun proteomics including protein extraction, digestion
and LC-MS/MS analysis. Proteins were further purified in a 6 M guanidine chloride and 10mM
HEPES-KOH buffer (pH 7.5) containing protease inhibitors before being followed by precipitation in
a methanol/chloroform/water (4:3:2 v/v/v) mixture. Precipitated proteins were resuspended in 6 M
Urea, 2 M thiourea, and 10 mM HEPES-KOH (pH 7.5). For reduction and alkylation, DTT (10 mM) and
iodoacetamide (50 mM) was added. Proteins were trypsin-digested overnight, and 1 µg was loaded
on the column for LC-MS/MS analysis. LC-MS/MS analysis was performed on a nano-LC-system
(Ultimate 3000 RSLC; Thermo Fisher Scientific) coupled to an Impact II high resolution quadrupole
time-of-flight (Bruker) using a Captive Spray nano electrospray ionization source (Bruker Daltonics).
The nano-LC system was equipped with an Acclaim Pepmap nanotrap column (C18, 100 Å, 700 µm 2
cm; Thermo Fisher Scientific) and an Acclaim Pepmap RSLC analytical column (C18, 100 Å, 75 µm × 50
cm; Thermo Fisher Scientific). The peptide mixture was fractionated by applying a linear gradient of 5%
to 45% acetonitrile at a flow rate of 250 nL min−1 over a period of 80 min. The column temperature was
set to 50◦C. MS1 spectra were acquired at 3 Hz with a mass range from m/z 200–2000, with the Top-15
most intense peaks selected for MS/MS analysis using an intensity-dependent spectra acquisition time
between 4 and 16 Hz. Dynamic exclusion duration was 0.5 min.
4.3. Data Analysis
Data analysis was performed by dedicated software for targeted (Skyline 4.2) and untargeted
analysis (metabolites: Compound Discoverer 3.0; lipids: Lipid Search 4.1, Compound Discoverer 3.0;
proteins: MaxQuant 1.6.2.10). For targeted analysis, normalization by 13C-labeled lipids/metabolites
and protein content was performed. For non-targeted data analysis, background correction (by
medium/blank samples) and normalization (mean-centered and divided by standard deviation in
MetaboAnalyst) was performed prior to further statistical and pathway analysis using MetaboAnalyst
4.0 [32]. Adipocyte samples had a higher variation than MSC cells, which was considered for statistical
analysis. Context-specific metabolic networks were reconstructed from shotgun proteomics data
applying the FASTCORE algorithm [55] using a consistent version of Recon 2.4 [56]. FASTCC [55]
was applied with the default flux activity threshold of 1e-4. Proteomic data was mapped to the
consistent version of Recon2.4 via the Gene Protein Association rules (GPR rules) to obtain a set of
core reactions, i.e., reactions that were found both in the proteomic data and the network model of
Recon2.4. FASTCORE were used to identify the missing reactions necessary to obtain a consistent
context-specific subnetwork for all differentiation states. OmicsNet was used for multiomics data
integration, visualization and pathway analysis [35].
Supplementary Materials: The following are available online at http://www.mdpi.com/1420-3049/24/19/3615/s1,
Table S1. Summary of the protein and lipid/metabolite data, Table S2. Regulated pathways comparing MSC
and adipocytes.
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Appendix A
Table S1. Summary of the protein and lipid/metabolite data. Lists of metabolite and lipid standards
used for targeted LC-MS. Protein IDs. Recon 2.4 pathway matches. Summary input list of identified
proteins (fasta numbers), lipids, and metabolites (human metabolome database numbers) using median
areas/concentrations for MSCs and adipocytes.
Table S2. Regulated pathways comparing MSC and adipocytes. Significantly regulated (p-value <
0.05) pathways identified by protein/metabolite network interaction using OmicsNet [35].
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Figure A3. Exemplary targeted quantification of metabolites and lipids. Compound-specific
quantification in MSCs (MSC0) and adipocytes (MSC21) using external calibration and standardization
by 13C-labeled matching compounds for (A) Normalization was performed by protein amounts and
autoscaling in MetaboAnalyst 4.0 [32]. For amino acids such as asparagine, general downregulation in
adipocytes was observed. For lipids and lipid precursors such as TG 54:3 (B) or carnitine (C), a trend
towards upregulation in adipocytes was observed. Data is represented as median ± upper/lower
quartile (n = 3).
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Figure A6. Carnitine and di- and triglyceride regulation in adipogenic differentiation. Example
networks of metabolite-protein interaction analysis using OmicsNet [35] (A) Triglyceride and diglyceride
regulation in adipocytes. The blue labeling highlights the glycerophospholipid proteins. (B) Carnitine
network. The blue labeling highlights proteins of the peroxisomal proliferator-activated receptor (PPAR)
signaling pathway, green label of peroxisomal carnitine O-octanoyltransferase (CROT gene): Transport
of medium- and long- chain acyl-coenzyme A(CoA) molecules out of the peroxisome to the cytosol and
mitochondria. The protein thus plays a role in lipid metabolism and fatty acid beta-oxidation.
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Appendix B
Supplementary Information
LC-MS Assay for Lipids and Metabolites- HILIC-RP-MS Dual Injection Setup
A recently published HILIC-RP-MS method was applied based on a Vanquish Duo UHPLC
system (Thermo Fisher Scientific) equipped with an autosampler with two injection units, two binary
pumps and a column compartment enabling parallel HILIC and RP analyses [28]. The temperature of
the autosampler was set to 10 ◦C.
For metabolite analysis, a SeQuant® ZIC®-pHILIC column (150 × 2.1 mm, 5 µm, polymer,
Merck-Millipore) was used with gradient elution under alkaline conditions with mobile phase A
being 90% 10 mM ammonium bicarbonate, pH 9.2/10% acetonitrile and mobile phase B being 100%
acetonitrile. A flow rate of 300 µL min−1, 5 µL injection volume (starting conditions) and 40 ◦C column
temperature was used with the following gradient: 0.0–6.0 min 75–45% B, 6.0–7.0 min decrease to 30%
B, 7.0–10.0 min 30% B and at 10.0 min switch to 75% B. From 15 to 27 min, the flow rate was reduced
to 50 µL min−1 in order to save solvents during RP elution and the injector needle was washed with
40% MeOH.
For lipid analysis, an Acquity HSS T3 (2.1 mm × 150 mm, 1.8 µm, Waters) with a VanGuard
Precolumn (2.1 mm × 5 mm, 100 Å, 1.8 µm) was applied. The flow rate was set to 250 µL min−1,
the injection volume 5 µL and the column temperature to 40 ◦C using ACN/H2O (3:2, v/v) as solvent A
and IPA/ACN (9:1, v/v) as solvent B. Both solvents contained 0.1% formic acid and 10 mM ammonium
formate and the following gradient was used: 0–12.0 min 30% B, 12.0–25.0 min ramp to 75% B, 25.0–27.0
ramp to 100% B, 27.0–32.0 100% B, 32.0 min fast switch to 30% B. Equilibration of minimum at least
5 min required was continued during the following HILIC injection. The injector needle was washed
with 75% IPA, 25% H2O, and 0.1% formic acid for 5 s prior to each injection.
Postcolumn 2-position 6-port valves were installed, respectively, followed by a T-piece prior to the
introduction into the MS. Two orthogonal separations were performed consecutively (HILIC: 0–11 min;
RP: 11–32 min), while the other separation eluent was directed to the waste. The dual-injection
sampler was programmed so that the metabolite and lipid extract were directed to the corresponding
autosampler. The analytical run was initialized upon injection of the metabolite sample onto the HILIC
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column, while the injection of the lipid sample was delayed by 10 min corresponding to the run time of
HILIC separation. The second injection on the RP column followed after 10 min and was synchronized
to the switching of the two postcolumn 6-port valves at 11 min. The RP separation was carried out
during the equilibration of the HILIC column with a total run time of 32 min.
High-resolution mass spectrometry was conducted on a high field Thermo Scientific™ Q Exactive
HF™ quadrupole-Orbitrap mass spectrometer equipped with an electrospray source. The ESI source
parameters were the following: sheath gas 40, auxiliary gas 3, spray voltage 2.8 kV in negative and
3.5 kV in the positive mode, capillary temperature 280 ◦C, S-Lens RF level 30 and auxiliary gas heater
320 ◦C. Spectral data were acquired in the profile mode. From 0 to 11 min full mass scan data in the
range of 65–975 m/z were acquired followed by 200–2000 m/z from 11 to 32 min for lipid analysis.
For the Full-MS quantification runs, positive mode data were acquired with a resolution of 120,000.
The automatic gain control (AGC) target was set to 1e6 and the maximum injection time (IT) was
200 ms and 100 ms for Full-MS and ddMS2 respectively. For identification, data-dependent MS2
(ddMS2) Top-15 fragmentation spectra were acquired in positive and negative modes separately with
a resolution of 30,000 for MS2. The ions were isolated with 1 m/z and fragmented with normalized
collision energies of NCE 30 for HILIC metabolites and 28 for RP lipids. The dynamic exclusion of
triggered m/z was set to 10 s. Iterative exclusion lists from pooled samples were generated using the
IE-Omics tool [59].
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